Cian Healthcare Ltd Stock Price Today (NSE: CHCL)
Fundamental Score
Cian Healthcare Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Cian Healthcare Ltd share price today is ₹36.23, up +2.00% on NSE/BSE as of 6 November 2026. Cian Healthcare Ltd (CHCL) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹6.21 (Cr). The 52-week high for CHCL share price is ₹73.03 and the 52-week low is ₹4.72. The company has a Return on Equity (ROE) of -102.80% and a debt-to-equity ratio of 3.36.
Cian Healthcare Ltd Share Price Chart — NSE/BSE Historical Performance
Cian Healthcare Ltd share price chart: 64.48% return over the past month. 52-week high ₹73.03, 52-week low ₹4.72.
Cian Healthcare Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹36.23 | ₹36.23 | ₹36.23 | ₹36.23 | 274.00 (Cr) | |
| ₹35.52 | ₹35.52 | ₹35.52 | ₹35.52 | 411.00 (Cr) | |
| ₹34.83 | ₹34.83 | ₹34.83 | ₹34.83 | 274.00 (Cr) | |
| ₹34.15 | ₹34.15 | ₹34.15 | ₹34.15 | 548.00 (Cr) | |
| ₹33.49 | ₹33.49 | ₹33.49 | ₹33.49 | 411.00 (Cr) | |
| ₹32.84 | ₹32.84 | ₹32.84 | ₹32.84 | 137.00 (Cr) | |
| ₹32.20 | ₹32.20 | ₹32.20 | ₹32.20 | 822.00 (Cr) | |
| ₹31.57 | ₹31.57 | ₹31.57 | ₹31.57 | 411.00 (Cr) | |
| ₹30.96 | ₹30.96 | ₹30.96 | ₹30.96 | 685.00 (Cr) | |
| ₹30.36 | ₹30.36 | ₹30.36 | ₹30.36 | 685.00 (Cr) |
Cian Healthcare Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹34.15 | ₹36.23 | ₹34.15 | ₹36.23 | +6.09% | |
| ₹24.48 | ₹33.49 | ₹24.48 | ₹33.49 | +36.81% | |
| ₹12.16 | ₹24.00 | ₹12.16 | ₹24.00 | +97.37% | |
| ₹9.55 | ₹11.04 | ₹9.55 | ₹11.04 | +15.60% | |
| ₹8.26 | ₹9.55 | ₹8.26 | ₹9.55 | +15.62% | |
| ₹8.26 | ₹8.26 | ₹8.26 | ₹8.26 | +0.00% | |
| ₹8.26 | ₹8.26 | ₹8.26 | ₹8.26 | +0.00% | |
| ₹73.03 | ₹73.03 | ₹7.50 | ₹8.26 | -88.69% | |
| ₹73.03 | ₹73.03 | ₹73.03 | ₹73.03 | +0.00% | |
| ₹73.03 | ₹73.03 | ₹73.03 | ₹73.03 | +0.00% | |
| ₹5.58 | ₹73.03 | ₹4.74 | ₹73.03 | +1208.82% | |
| ₹5.84 | ₹5.84 | ₹4.72 | ₹5.48 | -6.16% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Cian Healthcare Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Cian Healthcare Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of CHCL across key market metrics for learning purposes.
Positive Indicators
4 factors identified
Robust Profit Growth (37.58%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (42.69%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Strong Cash Generation (₹67.43 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
8 factors identified
Below-Average Return on Equity (-102.80%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-62.10%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Limited Growth History (-17.43% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Elevated Debt Levels (D/E: 3.36)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.
Weak Interest Coverage (-107.12x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Liquidity Concerns (Current Ratio: 0.78)
Observation: Current assets may not adequately cover short-term liabilities.
Analysis: Current ratio <1.0 raises working capital concerns.
Limited Public Float (95.00% Promoter Holding)
Observation: High promoter holding may restrict liquidity and price discovery.
Analysis: Very high promoter holding can limit trading liquidity.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Cian Healthcare Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Cian Healthcare Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Cian Healthcare LtdCian Healthcare...Selected✓ CHCL • 542678 | 34.1/100 | ₹36.23₹36 | ₹6.21₹6.21 | — — | -102.80%Poor -102.80% Poor | -62.10%Poor -62.10% Poor | 3.36Poor 3.4 Poor | — — | -17.43%Poor -17.43% Poor | 0.00% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 72.9/100 | ₹1758.80₹1759 | ₹421988.88₹421988.88 | 34.90Average 34.9 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 67.2/100 | ₹9144.50₹9145 | ₹242329.25₹242329.25 | 82.97Average 83.0 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 54.8/100 | ₹4558.90₹4559 | ₹154300.53₹154300.53 | 72.83Average 72.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 71.6/100 | ₹1123.00₹1123 | ₹112075.40₹112075.40 | 25.03Average 25.0 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 53.5/100 | ₹2060.10₹2060 | ₹111296.90₹111296.90 | 101.68Average 101.7 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 35.2/100 | ₹1325.10₹1325 | ₹107048.20₹107048.20 | 31.75Average 31.7 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 36.5/100 | ₹1233.00₹1233 | ₹102955.50₹102955.50 | 31.87Average 31.9 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1666.90₹1667 | ₹95913.43₹95913.43 | 26.05Average 26.0 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 59.7/100 | ₹2275.50₹2276 | ₹93978.15₹93978.15 | 45.98Average 46.0 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 77.1/100 | ₹1961.60₹1962 | ₹89694.16₹89694.16 | 16.21Average 16.2 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price421988.88 Cr
- Divi's Laboratories Limited share price242329.25 Cr
- Torrent Pharmaceuticals Limited share price154300.53 Cr
- Zydus Lifesciences Limited share price112075.40 Cr
- Laurus Labs Limited share price111296.90 Cr
Cian Healthcare Ltd Quarterly Performance
Latest quarterly metrics for CHCL — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
42.69%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
37.58%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
-17.43%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Cian Healthcare Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for CHCL — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Cian Healthcare Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Cian Healthcare Ltd (CHCL) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Cian Healthcare Ltd
About CHCL (Cian Healthcare Ltd)
Cian Healthcare Ltd is a dynamic pharmaceutical company dedicated to improving lives through innovative healthcare solutions. Operating primarily in India, CHCL focuses on the enti...re lifecycle of drug development, from rigorous research and meticulous development to efficient manufacture and strategic marketing. The company prides itself on its commitment to quality and patient well-being, striving to provide accessible and affordable medications that address a wide spectrum of health needs. CHCL aims to be a trusted partner for healthcare professionals and patients alike, driven by a mission to enhance the quality of life through pharmaceutical excellence. CHCL's product portfolio reflects its comprehensive approach to healthcare, encompassing a diverse range of therapeutic areas. From specialized treatments in gynecology and critical cardio-diabetic medications to essential orthopedic and pediatric formulations, CHCL caters to the varied needs of a growing population. The company also recognizes the increasing importance of preventative care, offering a range of vitamins, nutrients, and dermacosmetic products designed to promote overall health and well-being. With a commitment to addressing evolving healthcare challenges, CHCL continuously expands its product offerings through active research and strategic collaborations. Beyond traditional pharmaceuticals, Cian Healthcare Ltd acknowledges and addresses specific unmet medical needs within the community. This proactive approach is exemplified through their commitment to providing specialized products in areas such as male and female infertility, contributing to reproductive wellness. Furthermore, the company recognizes the importance of cognitive health and offers products aimed at energy boosting and supporting individuals with autism. By focusing on these crucial areas, CHCL demonstrates a dedication to comprehensive healthcare and a commitment to improving the lives of individuals across diverse demographics and needs.
Company Details
Key Leadership
CHCL Share Price: Frequently Asked Questions
What is the current share price of Cian Healthcare Ltd?
Cian Healthcare Ltd (CHCL) trades at ₹36.23 on NSE and BSE. Market cap ₹6.21 (Cr). Educational data only.
What is the P/E ratio of Cian Healthcare Ltd?
Cian Healthcare Ltd has a P/E of N/Ax vs industry average 34.89x.
What is the Bull Run score for Cian Healthcare Ltd?
Cian Healthcare Ltd has a Bull Run score of 34.1/100 based on 25+ financial parameters.
Does Cian Healthcare Ltd pay dividends?
Cian Healthcare Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Cian Healthcare Ltd?
Cian Healthcare Ltd has ROE of -102.80%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Cian Healthcare Ltd?
Cian Healthcare Ltd has debt-to-equity of 3.36.
Is Cian Healthcare Ltd a good investment?
Bull Run gives Cian Healthcare Ltd a score of 34.1/100. This is not investment advice — consult a SEBI-registered advisor.